Patents by Inventor Petra Simon

Petra Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumor Antigens for Determining Cancer Therapy
    Publication number: 20230355732
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Application
    Filed: February 28, 2023
    Publication date: November 9, 2023
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20230119334
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: August 21, 2022
    Publication date: April 20, 2023
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL
  • Tumor antigens for determining cancer therapy
    Patent number: 11628209
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 18, 2023
    Assignees: Tron GGMBH, BioNTech SE
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20220306711
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: April 4, 2022
    Publication date: September 29, 2022
    Inventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina Anna MROZ
  • ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
    Publication number: 20220288180
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Application
    Filed: February 24, 2022
    Publication date: September 15, 2022
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Claudin-6-specific immunoreceptors and t cell epitopes
    Patent number: 11345731
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: May 31, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, TRON-Translationale Onkologie An Der Universitatsmedzin Der Johannes Gutenberg-Universitat Mainz, Ganymed Pharmaceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • Antigen-specific T cell receptors and T cell epitopes
    Patent number: 11311611
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: April 26, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitätsmedizin der Johannes Gutenbera-Universität Mainz Gemeinnützine GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20220033461
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: September 18, 2021
    Publication date: February 3, 2022
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL
  • ENHANCING THE EFFECT OF CAR-ENGINEERED T CELLS BY MEANS OF NUCLEIC ACID VACCINATION
    Publication number: 20200360438
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 19, 2020
    Inventors: Ugur SAHIN, Katharina REINHARD, Petra SIMON, Karolina Anna MROZ, Kathleen HOBOHM
  • Enhancing the effect of car-engineered T cells by means of nucleic acid vaccination
    Patent number: 10799534
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: October 13, 2020
    Assignees: BIONTECH CELL & GENE THERAPIES GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÁTSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Ugur Sahin, Katharina Reinhard, Petra Simon, Karolina Anna Mroz, Kathleen Hobohm
  • ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20200063101
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: March 14, 2018
    Publication date: February 27, 2020
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Petra SIMON, Matthias BIRTEL, Janina CASPAR
  • Method and kit for determining whether a subject shows an immune response
    Patent number: 10550430
    Abstract: The present invention relates to a kit and a method for determining whether a subject shows an immune response against an antigen.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 4, 2020
    Assignees: BIONTECH DIAGNOSTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Michael Schäfer, Marta Magdalena Faryna, Tana Omokoko, Lisa Hebich, Petra Simon, Annett Reichardt, Özlem Öz
  • CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20190389920
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 26, 2019
    Inventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina Anna MROZ
  • Claudin-6-specific immunoreceptors and T cell epitopes
    Patent number: 10370423
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: August 6, 2019
    Assignees: Biotech Cell & Gene thrapies GMBH, Tron—Translationale Onkologie Ander Universitata tsmedizin Der Johannes Gutenberg-Universitat Main, Ganymed Pharmceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • TUMOR ANTIGENS FOR DETERMINING CANCER THERAPY
    Publication number: 20190192643
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 27, 2019
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
    Publication number: 20190060430
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Application
    Filed: September 4, 2018
    Publication date: February 28, 2019
    Applicants: BioNTech Cell & Gene Therapies GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Tumor antigens for determining cancer therapy
    Patent number: 10188712
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 29, 2019
    Assignees: BIONTECH AG, TRON—Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • Antigen-specific T cell receptors and T cell epitopes
    Patent number: 10117918
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: November 6, 2018
    Assignees: BioNTech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige Gmbh
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • CLAUDIN-18.2-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20180282389
    Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: May 9, 2016
    Publication date: October 4, 2018
    Inventors: Ugur SAHIN, Ozlem TÜRECI, Petra SIMON, Tana OMOKOKO, Andrea BREITKREUZ, Karolina Anna MROZ, Lisa HEBICH
  • ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20180282390
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 4, 2018
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL